keyword
MENU ▼
Read by QxMD icon Read
search

gleason grades

keyword
https://www.readbyqxmd.com/read/28820750/the-new-realization-about-cribriform-prostate-cancer
#1
Kenneth A Iczkowski, Gladell P Paner, Theodorus Van der Kwast
Data from the past 6 years have shown that the presence of any amount of cribriform (or more comprehensively, large acinar cribriform to papillary) pattern of invasive prostate cancer is associated with adverse pathologic features and leads to uniquely adverse outcomes. Sixteen papers and numerous abstracts have reached these conclusions concordantly. Not only does this justify removal of all cribriform cancer from Gleason grade 3, it shows that cribriform cancer has pathologic, outcome, and molecular features distinct from noncribriform Gleason grade 4...
August 17, 2017: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/28801885/active-surveillance-for-intermediate-risk-prostate-cancer
#2
REVIEW
Laurence Klotz
PURPOSE OF REVIEW: Active surveillance is now widely utilized for the management of low-risk prostate cancer (PCa). The limits of surveillance for men with intermediate risk cancer are controversial. While there is a broad consensus that men with low-risk disease can be safely managed with AS, many potential candidates, including those with Gleason 3 + 4 disease, PSA >10, younger men and African-Americans are often excluded. RECENT FINDINGS: Outcome data for intermediate-risk patients managed by active surveillance demonstrate reasonable outcomes, but these men clearly are at higher risk for progression to metastatic disease...
August 11, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28800492/adding-abiraterone-to-androgen-deprivation-therapy-in-men-with-metastatic-hormone-sensitive-prostate-cancer-a%C3%A2-systematic-review-and-meta-analysis
#3
Larysa H M Rydzewska, Sarah Burdett, Claire L Vale, Noel W Clarke, Karim Fizazi, Thian Kheoh, Malcolm D Mason, Branko Miladinovic, Nicholas D James, Mahesh K B Parmar, Melissa R Spears, Christopher J Sweeney, Matthew R Sydes, NamPhuong Tran, Jayne F Tierney
BACKGROUND: There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review aims to assess the effects of adding abiraterone acetate plus prednisone/prednisolone (AAP) to ADT. METHODS: Using our framework for adaptive meta-analysis (FAME), we started the review process before trials had been reported and worked collaboratively with trial investigators to anticipate when eligible trial results would emerge...
August 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28796935/focal-irreversible-electroporation-as-primary-treatment-for-localized-prostate-cancer
#4
Willemien van den Bos, Matthijs J Scheltema, Amila R Siriwardana, Anton M F Kalsbeek, James E Thompson, Francis Ting, Maret Böhm, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Phillip D Stricker
OBJECTIVES: To determine the safety, quality of life (QoL) and short-term oncological outcomes of primary focal IRE for the treatment of localized prostate cancer. To identify potential risk factors for oncological failure. PATIENTS AND METHODS: Patients that met both the consensus guidelines on patient criteria and selection methods for primary focal therapy were eligible for analysis. Focal IRE was performed for organ-confined clinically significant PCa, being high-volume Gleason sum score 6 (ISUP grade 1) or any Gleason sum score 7 (ISUP grade 2-3)...
August 10, 2017: BJU International
https://www.readbyqxmd.com/read/28790115/msh2-loss-in-primary-prostate-cancer
#5
Liana Guedes, Emmanuel S Antonarakis, Michael T Schweizer, Nooshin Mirkheshti, Fawaz Almutairi, Jong Chul Park, Stephanie A Glavaris, Jessica L Hicks, Mario A Eisenberger, Angelo M De Marzo, Jonathan I Epstein, William B Isaacs, James R Eshleman, Colin C Pritchard, Tamara L Lotan
PURPOSE: Inactivation of mismatch repair (MMR) genes may predict sensitivity to immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with MMR defects. EXPERIMENTAL DESIGN: 1133 primary prostatic adenocarcinomas and 43 prostatic small cell carcinomas (NEPC) were screened by MSH2 immunohistochemistry with confirmation by next-generation sequencing (NGS). Microsatellite instability (MSI) was assessed by PCR and NGS (mSINGS). RESULTS: Of primary adenocarcinomas and NEPC, 1...
August 8, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28789947/impact-of-5%C3%AE-reductase-inhibitors-on-disease-reclassification-among-men-on-active-surveillance-for-localized-prostate-cancer-with-favorable-features
#6
Charles Dai, Vishnu Ganesan, Joseph Zabell, Yaw A Nyame, Nima Almassi, Daniel J Greene, Daniel Hettel, Chad Reichard, Samuel C Haywood, Hans Arora, Anna Zampini, Alice Crane, Jianbo Li, Ahmed Elshafei, Cristina Magi-Galluzzi, Robert J Stein, Khaled Fareed, Michael Gong, J Stephen Jones, Eric A Klein, Andrew J Stephenson
PURPOSE: To determine the effect of 5α-reductase inhibitors (5-ARI) on disease reclassification in men with prostate cancer optimally selected for active surveillance (AS). MATERIALS AND METHODS: A retrospective review identified 635 patients on AS between 2002-2015. Patients with favorable cancer features on repeat biopsy, defined as absence of Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride/dutasteride within 1 year of diagnosis...
August 5, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28782737/contemporary-grading-of-prostate-cancer-2017-update-for-pathologists-and-clinicians
#7
Silvia Gasparrini, Alessia Cimadamore, Marina Scarpelli, Francesco Massari, Andrea Doria, Roberta Mazzucchelli, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi
The Gleason grading system for prostate cancer (PCa) was developed in the 1960s by DF Gleason. Due to changes in PCa detection and treatment, the application of the Gleason grading system has changed considerably in pathology routine practice. Two consensus conferences were held in 2005 and in 2014 to update PCa Gleason grading. This review provides a summary of the changes in the grading of PCa from the original Gleason grading system to the prognostic grade grouping, as well as a discussion of the clinical significance of the percentage of Gleason patterns 4 and 5...
August 4, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/28781111/creation-and-internal-validation-of-a-biopsy-avoidance-prediction-tool-to-aid-in-the-choice-of-diagnostic-approach-in-patients-with-prostate-cancer-suspicion
#8
Bimal Bhindi, Haiyan Jiang, Cedric Poyet, Thomas Hermanns, Robert J Hamilton, Kathy Li, Ants Toi, Antonio Finelli, Alexandre R Zlotta, Theodorus H van der Kwast, Andrew Evans, Neil E Fleshner, Girish S Kulkarni
INTRODUCTION: To reduce unnecessary prostate biopsies while using novel tests judiciously, we created a tool to predict the probability of clinically significant prostate cancer (CSPC) vs. low-risk prostate cancer or negative biopsy (i.e., when intervention is likely not needed) among men undergoing initial or repeat biopsy. METHODS: Separate models were created for men undergoing initial and repeat biopsy, identified from our institutional biopsy database and the placebo arm of the REDUCE trial, respectively, to predict the presence of CSPC (Gleason≥7 or>33% of cores involved)...
August 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28768264/pathological-concordance-between-prostate-biopsies-and-radical-prostatectomy-using-transperineal-sector-mapping-biopsies-validation-and-comparison-with-transrectal-biopsies
#9
Giancarlo Marra, David Eldred-Evans, Ben Challacombe, Mieke Van Hemelrijck, Alexander Polson, Sabine Pomplun, Christopher S Foster, Christian Brown, Declan Cahill, Paolo Gontero, Rick Popert, Gordon Muir
Background/Aims/Objectives: Our aim was to evaluate the accuracy of systematic transperineal sector mapping biopsy (TPSMB) in predicting Gleason score (GS) at radical prostatectomy (RP), to compare its accuracy with standard transrectal ultrasound-guided biopsies (TRUS) and to establish the clinical impact of discordance between biopsies and RP on subsequent surgical management. METHODS: Two hundred fifty-five patients from 2008 to 2013 who underwent RP following TPSMB (n = 204) or TRUS (n = 51), were included in this retrospective multi-institutional study...
July 29, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28766961/hoxa13-is-associated-with-unfavorable-survival-and-acts-as-a-novel-oncogene-in-prostate-carcinoma
#10
Yan Dong, Ying Cai, Bo Liu, Xiang Jiao, Zhong-Tai Li, Da-Yong Guo, Xin-Wei Li, Yong-Jun Wang, Deng-Ke Yang
AIM: To investigate the clinical relevance and functional role of HOXA13 in prostate cancer Methods: PCR, western blot and immunohistochemistry were performed to determine the expression. Kaplan-Meier and Cox regression survival analyses investigated the clinical relevance. Cell viability, flow cytometry and transwell assays were used to determine the functional roles. RESULTS: HOXA13 expression is sharply increased in carcinoma tissues and is significantly associated with poor prognosis of prostate cancer patients...
July 2017: Future Oncology
https://www.readbyqxmd.com/read/28761588/salvage-prostatectomy-for-post-radiation-adenocarcinoma-with-treatment-effect-pathological-and-oncological-outcomes
#11
Michael J Metcalfe, Patricia Troncoso, Charles C Guo, Hsiang-Chun Chen, Yasar Bozkurt, John F Ward, Louis L Pisters
INTRODUCTION: Prostate biopsies following localized radiation therapy for prostate cancer often demonstrate residual prostatic carcinoma with treatment effect (CTE). The final oncological outcome of prostatic CTE is currently uncertain. We studied the pathological and oncological outcomes for a large cohort of patients who had CTE on post-radiation therapy biopsy and subsequently underwent salvage radical prostatectomy (SRP). METHODS: A single-centre retrospective review of all SRPs performed from 1995-2014 was performed...
July 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28760556/bone-scan-index-is-an-independent-predictor-for-time-to-castration-resistant-prostate-cancer-in-newly-diagnosed-prostate-cancer-a-prospective-study
#12
Helle D Zacho, Michael Gade, Jesper C Mortensen, Henrik Bertelsen, Ren K Boldsen, Tamás Barsi, Lars J Petersen
OBJECTIVE: To prospectively determine the prognostic value of the bone scan index (BSI) for time to development of castration-resistant prostate cancer (CRPC) in consecutive, hormone-naïve patients with newly diagnosed prostate cancer. PATIENTS AND METHODS: Eligible patients participated in a prospective, observational, multi-center study of the value of bone scintigraphy (BS) at staging. BSI was determined using the EXINIBone(BSI)-software in 208 consecutive patients undergoing androgen deprivation therapy...
July 28, 2017: Urology
https://www.readbyqxmd.com/read/28753847/incidence-risk-factors-management-and-complications-of-rectal-injuries-during-radical-prostatectomy
#13
Philipp Mandel, Anna Linnemannstöns, Felix Chun, Thorsten Schlomm, Raisa Pompe, Lars Budäus, Clemens Rosenbaum, Tim Ludwig, Roland Dahlem, Margit Fisch, Markus Graefen, Hartwig Huland, Derya Tilki, Thomas Steuber
Rectal injury (RI) during radical prostatectomy (RP) is a severe complication. So far, only limited data describing the incidence, risk factors, management, and complications of RI are available. In an analysis of data for 24178 patients, we identified 113/24076 patients (0.47%) undergoing open or robotic RP and 7/102 patients (6.86%) after salvage RP who experienced an RI. Besides salvage RP, local tumor stage, Gleason grade, lymph node status, and surgical experience, but not surgical approach (robotic vs open), could be identified as risk factors for RI in univariate and multivariate analysis...
February 7, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753846/the-landscape-of-whole-genome-alterations-and-pathologic-features-in-genitourinary-malignancies-an-analysis-of-the-cancer-genome-atlas
#14
Mark W Ball, Michael A Gorin, Charles G Drake, Hans J Hammers, Mohamad E Allaf
BACKGROUND: The accumulation of somatic genetic alterations drives carcinogenesis. Little is known, however, about how the level of genetic alteration across an entire cancer genome affects tumor grade, stage or survival. OBJECTIVE: To investigate the influence of somatic mutation count (MC) and copy number variation (CNV) on pathologic and oncologic outcomes in patients with genitourinary malignancies in The Cancer Genome Atlas (TCGA). DESIGN, SETTING, AND PARTICIPANTS: TCGA data sets for adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), chromophobe renal cell carcinoma (RCC; KICH), clear cell RCC (KIRC), papillary RCC (KIRP), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), and testis germ cell tumor (TGCT) were accessed via cBioportal...
February 8, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753844/transcriptome-wide-analysis-of-magnetic-resonance-imaging-targeted-biopsy-and-matching-surgical-specimens-from-high-risk-prostate-cancer-patients-treated-with-radical-prostatectomy-the-target-must-be-hit
#15
Jan Philipp Radtke, Mandeep Takhar, David Bonekamp, Claudia Kesch, Nicholas Erho, Marguerite du Plessis, Christine Buerki, Kaye Ong, Elai Davicioni, Markus Hohenfellner, Boris A Hadaschik
BACKGROUND: The most suspicious lesions on multiparametric magnetic resonance imaging (MRI) may be representative of final pathology. OBJECTIVE: We connect imaging with high-precision spatial annotation of biopsies and genomic cancer signatures to compare the genomic signals of the index lesion and biopsy cores of adjacent and far away locations. DESIGN, SETTING, AND PARTICIPANTS: Eleven patients diagnosed with high-risk prostate cancer on MRI/transrectal ultrasound-fusion biopsy (Bx) and treated with radical prostatectomy (RP)...
January 26, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753831/balancing-overdiagnosis-and-early-detection-of-prostate-cancer-using-the-stockholm-3-model
#16
Tobias Nordström, Henrik Grönberg, Jan Adolfsson, Markus Aly, Martin Eklund
The S3M (Stockholm-3 Model) test improves discrimination for high-grade (Gleason score ≥ 7) prostate cancer compared with prostate-specific antigen (PSA) testing. Published results from the Stockholm-3 study represent a snapshot of possible outcomes for prostate cancer detection using the S3M test. In this brief report, we show how the full range of cancer detection rates and percent saved biopsies depend on the chosen S3M cut-off for recommending prostate biopsy. Using data from the Stockholm-3 validation cohort (n=47 688), we calculated the cancer detection rates and percent saved biopsies for various S3M test cut-offs in men with PSA ≥1ng/ml...
December 19, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28753811/risk-of-upgrading-and-upstaging-among-10-000-patients-with-gleason-3-4-favorable-intermediate-risk-prostate-cancer
#17
David D Yang, Brandon A Mahal, Vinayak Muralidhar, Michelle D Nezolosky, Marie E Vastola, Shelby A Labe, Ninjin Boldbaatar, Martin T King, Neil E Martin, Peter F Orio, Clair J Beard, Karen E Hoffman, Quoc-Dien Trinh, Daniel E Spratt, Felix Y Feng, Paul L Nguyen
BACKGROUND: It is unknown whether active surveillance can be safely offered to patients with Gleason 3+4 favorable intermediate-risk (FIR) prostate cancer. OBJECTIVE: To examine the incidence and predictors of upgrading and upstaging among patients with Gleason 3+4 FIR disease. DESIGN, SETTING, AND PARTICIPANTS: The study involved 10 089 patients in the National Cancer Database diagnosed from 2010 to 2012 with Gleason 3+4 disease, prostate-specific antigen (PSA) <10ng/ml, and cT1c-2a prostate cancer with <50% positive biopsy cores (PBCs) who underwent radical prostatectomy...
June 17, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753797/-18-f-dcfpyl-positron-emission-tomography-magnetic-resonance-imaging-for-localization-of-dominant-intraprostatic-foci-first-experience
#18
Glenn Bauman, Peter Martin, Jonathan D Thiessen, Reggie Taylor, Madeleine Moussa, Mena Gaed, Irina Rachinsky, Zahra Kassam, Joseph Chin, Stephen Pautler, Ting Yim Lee, John F Valliant, Aaron Ward
An ongoing prospective study is acquiring preoperative imaging data for men with prostate cancer (PCa) using the molecular imaging agent [(18)F]-DCFPyL targeted against prostate-specific membrane antigen (PSMA). To date, six men (of a planned accrual of 24) with clinically localized, biopsy-proven PCa have undergone preoperative [(18)F]-DCFPyL positron emission tomography (PET) imaging and multiparametric magnetic resonance imaging acquired using a hybrid PET/MRI system. Lesions identified by [(18)F]-DCFPyL uptake on PET/MRI were characterized in terms of maximum standardized uptake value (SUVmax) and volume using a boundary threshold of 40% SUVmax...
October 26, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28749167/diagnostic-value-of-semiquantitative-and-quantitative-analysis-of-functional-parameters-in-multiparametric-mri-of-the-prostate
#19
Elke Hauth, Daniela Halbritter, Horst Jaeger, Horst Hohmuth, Meinrad Beer
OBJECTIVES: To determine the diagnostic value of semiquantitative and quantitative parameters of three functional techniques in multiparametric (mp)-MRI of the prostate. METHODS: Mp-MRI was performed in 110 patients with suspicion of prostate cancer (PCA) before TRUS-guided core biopsy. Peak-enhancement, initial and post-initial enhancement, iAUGC (initial area under gadolinium curve), Ktrans (forward rate constant), Kep (efflux rate constant), Ve (extracellular volume), ADC (apparent diffusion coefficient), and MR spectroscopy ratio were obtained for malignant and benign lesions...
July 27, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28749070/diagnostic-accuracy-of-magnetic-resonance-imaging-mri-5-point-likert-scoring-system-evaluated-by-the-result-of-mri-ultrasonography-image-fusion-targeted-biopsy-of-the-prostate
#20
Toshitaka Shin, Thomas B Smyth, Osamu Ukimura, Nariman Ahmadi, Andre Luis de Castro Abreu, Chisato Ohe, Masakatsu Oishi, Hiromitsu Mimata, Inderbir S Gill
OBJECTIVE: To evaluate the accuracy of MRI based Likert scoring system in detection of clinically significant prostate cancer (CSPC) using MRI/Ultrasonography (US) image-fusion targeted biopsy (FTB) as a reference standard. PATIENTS AND METHODS: We retrospectively reviewed 1218 MRI-lesions in 629 patients who underwent subsequent MRI/US FTB between 10/2012 and 8/2015. 3-Tesla MRI was independently reported by 1 of 8 radiologists with varying levels of experience and scored on a 5-point Likert scale...
July 27, 2017: BJU International
keyword
keyword
98250
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"